Clinical Trial Update: Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) [NA]

View source ↗

Summary

A clinical trial comparing bevacizumab to micropulse laser therapy for central serous chorioretinopathy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Serous Chorioretinopathy

Drugs mentioned

• Bevacizumab (bevacizumab)

Snippet

Sponsor: Johann Wolfgang Goethe University Hospital | Conditions: Central Serous Chorioretinopathy | NA | Status: COMPLETED